-
Product Insights
Diabetic Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Diabetic Gastroparesis - Drugs In Development, 2023’, provides an overview of the Diabetic Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Biliary Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Biliary Tumor - Drugs In Development, 2023’, provides an overview of the Biliary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Tumor - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roducitabine in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Roducitabine in Metastatic Pancreatic Cancer Drug Details: Roducitabine is under development for the treatment of...
-
Product Insights
NewNet Present Value Model: Satsuma Pharmaceuticals Inc’s Dihydroergotamine Mesylate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YH-12852 in Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YH-12852 in Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YH-12852 in Gastroparesis Drug Details: YH-12852 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YH-12852 in Diabetic Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YH-12852 in Diabetic Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.YH-12852 in Diabetic Gastroparesis Drug Details:YH-12852 is under development for the treatment of...